Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease.

AIMS The prognostic role of inflammation in peripheral arterial disease (PAD) remains to be conclusively established. Accordingly, in these patients we investigated the impact of myeloperoxidase (MPOx) and C-reactive protein on the incidence of myocardial infarction and stroke. METHODS AND RESULTS Of 156 PAD patients, 10 had a myocardial infarction and seven a stroke, during follow-up. We used the receiver operating characteristic curve analysis and the bootstrap approach to identify the MPOx, C-reactive protein, and ankle brachial index (ABI) threshold levels that provided the best cut-off to predict the outcome. For MPOx a cut-off > or =183.7 pM was independently associated with a poor outcome (HR = 6.80, 95% CI 1.20-38.69, P = 0.031). The result remained unmodified when MPOx was used as a continuous variable (HR = 1.03, 95% CI 1.01-1.05, P = 0.031). Conversely, C-reactive protein was not a prognostic determinant in our series (HR = 0.88, 95% CI 0.60-1.29, P = 0.514). Kaplan-Meier curves for the four groups of patients delineated according to ABI and MPOx values identified using the bootstrap approach showed that the addition of MPOx measurement to ABI improved the ability to identify patients at risk for myocardial infarction and stroke. CONCLUSION In PAD, MPOx, but not C-reactive protein, predicts an increased risk of major cardiovascular events, and adds to the prognostic value of ABI, currently the most powerful prognostic indicator in these patients.

[1]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[2]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[3]  S. Yusuf,et al.  Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.

[4]  Eric Boerwinkle,et al.  An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.

[5]  J. Chen,et al.  Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. , 2005, The American journal of cardiology.

[6]  P. Ridker,et al.  Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). , 2005, The American journal of cardiology.

[7]  Ioanna Tzoulaki,et al.  C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population: Edinburgh Artery Study , 2005, Circulation.

[8]  E. Twiss,et al.  C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. , 2005, Journal of vascular surgery.

[9]  P. Hildebrandt,et al.  N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.

[10]  M. Chiariello,et al.  Adhesion molecules and cardiovascular risk in peripheral arterial disease , 2005, Thrombosis and Haemostasis.

[11]  J. Kaski,et al.  Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris , 2004, Circulation.

[12]  Marlene Goormastic,et al.  Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans , 2004, Circulation.

[13]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[14]  C. Zincarelli,et al.  Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease , 2003, Vascular medicine.

[15]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[16]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[17]  M. Chiariello,et al.  Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis , 2003, Thrombosis and Haemostasis.

[18]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[19]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[20]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[21]  K. Huber,et al.  High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. , 2002, American heart journal.

[22]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[23]  Chunxiang Zhang,et al.  Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.

[24]  A. Maseri,et al.  Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease , 2002 .

[25]  A. Maseri,et al.  Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease: Predictive Role of C-Reactive Protein , 2002, Circulation.

[26]  E J Topol,et al.  Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.

[27]  W. Parks,et al.  Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7) , 2001, The Journal of Biological Chemistry.

[28]  E. Falk,et al.  Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors? , 2001, Journal of the American College of Cardiology.

[29]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[30]  P. Libby,et al.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. , 2001, The American journal of pathology.

[31]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[32]  A. von Eckardstein,et al.  C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. , 2000, European heart journal.

[33]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[34]  G. Breithardt,et al.  Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[36]  N. Powe,et al.  Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[37]  G Pasterkamp,et al.  Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  F. Cacciatore,et al.  Intermittent Claudication and Risk of Cardiovascular Events , 1998, Angiology.

[39]  Arno W. Hoes,et al.  Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[40]  F. Shabani,et al.  The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. , 1998, Free radical research.

[41]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[42]  R. Langer,et al.  Mortality over a period of 10 years in patients with peripheral arterial disease. , 1992, The New England journal of medicine.

[43]  P. Donnan,et al.  Validity of duplex scanning in the detection of peripheral arterial disease in the general population. , 1992, European journal of vascular surgery.

[44]  M. Bousser,et al.  Fate of the patient with chronic leg ischaemia. A review article. , 1989, The Journal of cardiovascular surgery.

[45]  S. Klebanoff.  Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.